Related Experiment Videos
Heart failure therapy with cilazapril: an overview
L Dössegger1, T Nielsen, C Preston
1F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Journal of Cardiovascular Pharmacology
|January 1, 1994
Summary
Cilazapril effectively treats chronic heart failure by improving cardiac function and symptoms. This ACE inhibitor demonstrated good tolerability and safety in patients with heart conditions.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Chronic heart failure (CHF) significantly impacts patient quality of life and prognosis.
- Ischemic heart disease and dilated cardiomyopathy are common etiologies of CHF.
Purpose of the Study:
- To investigate the efficacy and safety of cilazapril in patients with chronic heart failure.
- To evaluate the dose-dependent effects of cilazapril on hemodynamic parameters and clinical outcomes.
Main Methods:
- International clinical program involving patients with CHF.
- Placebo-controlled studies assessing cilazapril doses from 1.25-5 mg once daily.
- Long-term safety evaluation in 1,163 patients over varying treatment durations.
Main Results:
- Cilazapril demonstrated a dose-dependent reduction in pulmonary capillary wedge pressure and systemic vascular resistance, with increased cardiac index.
- Significant improvements were observed in exercise tolerance, New York Heart Association classification, and CHF symptoms.
- Adverse events like dizziness and cough were reported, with treatment discontinuation in 12.9% of patients.
Conclusions:
- Cilazapril is effective for once-daily treatment of chronic heart failure, even with concomitant therapies.
- The drug is generally well-tolerated in both young and elderly patients.
- Cardiac events were the primary cause of mortality in the study population.